Valeant Pharmaceuticals International Inc. (NYSE: VRX) completed a review of its accounting practices and has found no new items that would trigger a restatement of financials. The stock price surged $2.62 to close at $28.73.
Valeant Pharmaceuticals completes accounting review
April 05, 2016 at 17:08 PM EDT
